A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Trial status: Authorised ORR with PR-L as assessed by IRC, DOR as assessed by IRC and by investigator, PFS as assessed by IRC and by investigator, Complete response rate as assessed by IRC and by investigator, TTR as assessed by IRC and by investigator, OS, Including, but not limited to, incidence and severity of TEAEs, SAEs and TEAEs leading to study drug discontinuation, Changes from baseline in laboratory parameters and vital signs, Summary measures of PK trough concentrations, ORR (with and without PR-L) as assessed by investigator, PROs measured by EORTC QLQ-C30 and EQ-5D-5L questionnaires ORR (without PR-L) as assessed by IRC

ORR with PR-L as assessed by IRC, DOR as assessed by IRC and by investigator, PFS as assessed by IRC and by investigator, Complete response rate as assessed by IRC and by investigator, TTR as assessed by IRC and by investigator, OS, Including, but not limited to, incidence and severity of TEAEs, SAEs and TEAEs leading to study drug discontinuation, Changes from baseline in laboratory parameters and vital signs, Summary measures of PK trough concentrations, ORR (with and without PR-L) as assessed by investigator, PROs measured by EORTC QLQ-C30 and EQ-5D-5L questionnaires

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 41 participants